Efficacy of low dose azithromycin in recurrent furunculosis

Dr. Zaib, Farwa Naqvi, Sara Inayat, Amna Mubeen, Fida Muhammad, Ahmed Amin Khan Faraz, Muhammad Mustafa Qamar

Abstract


Aim To access the efficacy of low dose azithromycin in recurrent furunculosis.

 

Methods This study was conducted at the Outpatient Department of Dermatology, DHQ teaching Hospital, Sargodha Medical College Sargodha, from January 2019 to December 2019. Total 180 patients aged between 20 and 60 years of recurrent furunculosis were divided into two groups. Both groups washed body with chlorhexidine soap daily, applied 2% mupirocin on lesion and in nostrils twice daily and took oral 400mg -600mg tablet linezolid twice daily for 10-14 days. Group A was offered no added treatment but Group B was prescribed azithromycin 500mg once weekly for next 3 months. The drug is considered efficacious if the patient had no episode of furuncles during the 3‐month follow‐up period of the treatment.

 

Results  In group A, 32 patients (36%) reported back with recurrent furunculosis in contrast with only 9 patients (10%) of group A reported with recurrent furunculosis.

 

Conclusion It is concluded that low dose azithromycin is far better than patient receiving no treatment for recurrent furunculosis. So, we should consider low dose azithromycin as a promising alternative for treatment of recurrent furunculosis.

 


Keywords


Azithromycin; recurrent furunculosis

Full Text:

PDF

References


Jain AKC. Carbuncle is an Uncle of Furuncle‖–A case report. EAS J Med Surg. 2019;1(6):175–6.

Ibler KS, Kromann CB. Recurrent furunculosis–challenges and management: a review. Clin Cosmet Investig Dermatol. 2014;7:59.

Nowicka D, Grywalska E. Staphylococcus aureus and Host Immunity in Recurrent Furunculosis. Dermatology. 2019; 235(4): 295–305.

Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167(4):725–32.

Davido B, Dinh A, Salomon J, Roux AL, Gosset-Woimant M, Pierre I, et al. Recurrent furunculosis: Efficacy of the CMC regimen—skin disinfection (chlorhexidine), local nasal antibiotic (mupirocin), and systemic antibiotic (clindamycin). Scand J Infect Dis. 2013; 45(11):837–41.

Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. 2009; 33(4):374–8.

Aminzadeh A, Demircay Z, Ocak K, Soyletir G. Prevention of chronic furunculosis with low‐dose azithromycin. J Dermatolog Treat. 2007;18(2):105–8.

Renteria AE, Maniakas A, Mfuna LE, Asmar M, Gonzalez E, Desrosiers M. Low‐dose and long‐term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients. In: International Forum of Allergy & Rhinology. Wiley Online Library; 2020.

Shallcross LJ, Hayward AC, Johnson AM, Petersen I. Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care. Br J Gen Pract. 2015;65(639):e668–76.

Roudebush P, Schoenherr WD. Skin and hair disorders. Small Anim Clin Nutr. 2010;637–43.

Hamaliaka A, Novikova I. Nitric oxide production disorders in leukocytes of patients with recurrent furunculosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.2010;154(2):163–7.

Mashhood AA, Shaikh ZI, Qureshi SM, Malik SM. Efficacy of rifampicin in eradication of carrier state of Staphylococcus aureus in anterior nares with recurrent furunculosis. J Coll Physicians Surg Pak. 2006;16(6):396–9.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014